Amdocs Limited DOX ← Back to all reports

Amdocs Limited

DOX · Technology
A ★★★★ Buy
Aug 16, 2026 · Score 86 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $58.66
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $58.00 ($56.00–$60.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $81.62
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Methodology →
+39.1%

Type A - Amdocs Limited (DOX) 20260816 Stock Analysis

📅 Amdocs Key Upcoming Events

🏢 Step 1: Amdocs Company Overview & Business Model

Q1-A1. What is Amdocs?

Q1-A2. How Does Amdocs Make Money?

Q1-A3. Amdocs’s Revenue Segments & Core Income Sources

Q1-A4. Who Are Amdocs’s Competitors?

Q1-A5. Amdocs Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: Amdocs’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Amdocs Have a Durable Economic Moat?

Q2-A2. Is Amdocs’s Growth Sustainable?

Q2-A3. How Does Amdocs Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is Amdocs Profitable? Financial Health Analysis

Q3-A2. How Profitable Is Amdocs? (Margins & ROIC)

Q3-A3. What Drives Amdocs’s Returns? (ROIC Breakdown)

Q3-A4. Are Amdocs’s Earnings High Quality?

Q3-A5. Is Amdocs’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: Amdocs Forensic Accounting & Dilution Review

Q4-A1. Does Amdocs Have Accounting Red Flags?

Q4-A2. Is Amdocs Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is Amdocs’s Cash Flow?

Q4-A4. Is Amdocs Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: Amdocs Management & Shareholder Alignment

Q5-A1. Can You Trust Amdocs’s Management? (Guidance Track Record)

Q5-A2. What Are Amdocs Insiders Doing?

Q5-A3. Is Amdocs’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: Amdocs Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Amdocs Guidance

Q6-A2. What Is Amdocs’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: Amdocs Catalysts & Price Triggers

Q7-A1. What Could Move Amdocs Stock? (Top 3 Catalysts)

Q7-A2. Amdocs’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is Amdocs Fairly Valued? Valuation Analysis

Q8-A1. Amdocs’s Key Valuation Multiples (P/E, EV/EBITDA)

Q8-A2. Amdocs vs Peers: Valuation Comparison

Q8-A3. Is Amdocs Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into Amdocs? (Reverse DCF)

Q8-A4-1. What Growth Hurdle Does the Market Demand From Amdocs? (Reverse DCF Alternative)

Q8-A5. Valuation Cross-Check

Q8-A6. Amdocs’s Hidden Asset & Stake Valuation

Q8-A7. Final Valuation Adjustment

Q8-A8. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of Amdocs? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Amdocs?

Q9-A2. How Sensitive Is Amdocs to the Economy?

Q9-A3. Amdocs Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score

🎯 Step 10: Amdocs Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy Amdocs? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. Amdocs’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is Amdocs’s Heavy Revenue Concentration with AT&T and T-Mobile Its Biggest Weakness?

Q2: Can Amdocs’s Undemanding 7.5x Forward P/E Be Justified by the Launch of Its Agentic AI Platform (aOS)?

Q3: Will the Q3 2026 Restructuring Charge Permanently Elevate Amdocs’s Structural Operating Margins?

Q4: Does the Aggressive $1 Billion Share Repurchase Program Mask Underlying Fundamental Weakness?

Q5: How Vulnerable is Amdocs to Existential Encroachment from AWS and Microsoft Azure?

Q6: Can the New CEO, Shimie Hortig, Successfully Accelerate Amdocs’s Market Share in Europe?

Q7: Will the Rapid Proliferation of eSIM Technology Erode Amdocs’s Billing Moat?

Q8: Does the Simultaneous Transition of the CEO and CFO Introduce Unacceptable Execution Risk?

Q9: Does Amdocs Retain True Pricing Power During Managed Services Renewals?

Q10: Can Amdocs Successfully Monetize the Private 5G and B2B Enterprise Opportunity?